M	AR 1 0 2004		03-11-04 [jmale Express Mail Mailing Label No. EL653442806US							
	30;;;									
	RADEMARK			Serial Number	09/422,999					
		Filing Date		i	per 22, 1999					
			First Named	Inventor	Kawasaki					
TRAN	NSMITTA	L	Group Art U		1646					
			Examiner N	·	Murp					
_	FORM		Attorney Do	ocket No.	MIT-103					
			Patent No.		Not a	pplicable				
			Issue Date		Not a	pplicable				
		ENG	CLOSURES (c.	heck all that apply)						
Fee Transmittal	Form		Copy of Notice Parts of Applic	e to File Missing		Notice of Appeal to Board of Patent Appeals and Interferences				
🗍 Сору	c Attached of Fee mittal Form		Formal Drawin			Appeal Brief (in triplicate)				
☐ Amendme	ent/Response		Request For C			Status Inquiry				
☐ Prelin	ninary		Examination (I	RCE)	:					
After	Final		D		\boxtimes	Return Receipt Postcard				
Letter Draft:	avits/declaration(s) to Official sperson		Power of Attor (Revocation of	rney f Prior Powers)		Certificate of First Class Mailing under 37 C.F.R. 1.8				
	Drawings eets]		Terminal Disc	laimer		Certificate of Facsimile Transmission under 37 C.F.R. 1.8				
Petition fo	or Extension of			aration and Power r Utility or Design tion	⊠	Additional Enclosure(s) (please identify below) Associate Power of Attorney				
Information Disclosure Statement			Small Entity S	tatement	:					
⊠ Co			CD(s) for large	e table or computer						
	Copy of Priority		Amendment A	fter Allowance		Ť				
Document	t(s)		Request for Ce	ertificate of						
Paper Comp	Listing submission Copy/CD uter Readable Copy nent verifying ity of above		Correction	of Correction (in						
CORRESPONDEN			SIGNATURE BL	OCK	Respectfully submitted,					
Direct all correspon	Iministrator rwitz & Thet Tower Street 1A 02110 (617) 248- (617) 248-	nibeault, LLP	Date: March 10, 2004 Reg. No. 51,752 Tel. No.: (617) 248-8423 Fax No.: (617) 248-7100 Respectfully submitted, Junta M. M. D. D. Jeanifer G. Moitoso Attorney for Applicants Testa, Hurwitz & Thibeault, LLP High Street Tower 125 High Street Boston, MA 02110							

VER 12/00 3036265_1

Express Mail Mailing Label No. EL653442806US

FY 2004

	Complete if Known							
Application Serial Number	09/422,999							
Filing Date	October 22, 1999							
First Named Inventor	Kawasaki							
Group Art Unit	1646							
Examiner Name	Murphy, J.							
Attorney Docket No.	MIT-103							

METHOD OF PAYMENT	FEE CALCULATION (continued)						
1. A Payment Enclosed:	3. ADDI	TIONAL FE	EES				
☐ Check ☐ Money Order ☐ Other	Large	Small					
	Entity	Entity					
2. The Commissioner is hereby authorized to credit	Fee	Fee	Fee Description Fe	e Paid			
or charge any fee indicated below for this submission	(\$)	(\$)					
to Deposit Account No. 20-0531.	-						
Required Fees (copy of this sheet enclosed).	130	65	Surcharge - late filing fee or oath				
Additional fee required under 37 CFR 1.16 and	50	25	Surcharge - late provisional filing fee				
1.17.			or cover sheet				
Overpayment Credit.	130	130	Non-English specification				
Applicant claims small entity status.	2,520	2,520	Request for ex parte reexamination				
FEE CALCULATION	110	55	Extension for reply within first month				
1. FILING FEE	420	210	Extension for reply within second				
I. FILING FEE	1 720	210	month				
Large Entity	950	475	Extension for reply within third month				
Fee (\$) Fee Description Fee Paid	1480	740	Extension for reply within fourth				
ree (3) ree Description ree and			month				
	2010	1005	Extension for reply within fifth month				
770 Utility filing fee	330	165	Notice of Appeal				
340 Design filing fee	330	165	Filing a brief in support of an appeal				
160 Provisional filing fee	290	145	Request for oral hearing				
	130	130	Petitions to the Commissioner				
	180	180	Submission of Information Disclosure 18	0.00			
Number Number Rate Amount			Statement				
Filed Extra	770	385	Filing a submission after final				
	1		rejection (37 CFR 1.129(a))				
Total Claims $-20 = x $ 18.00 =$	770	385	For each additional invention to be				
••••••			examined (37 CFR 1.129(b))				
Independent	100	100	Certificate of Correction for				
Claims $-3 = x \$ 86.00 =$			applicant's error				
	110	55	Submission of Terminal Disclaimer				
☐ Multiple Dependent Claim(s), if any \$290.00 =	Other fee (Sp						
	Other fee (Sp	pecify)					
TOTAL:							
SMALL ENTITY DISCOUNT:	1						
SUBTOTAL (1) (\$) 0.00							
2. AMENDMENT CLAIM FEES	SUBTOTAL (3) (\$) 180.00						
Claims Highest No. Present Rate Fee Paid	SUBTOTAL (3) (\$) 180.00						
Remaining Previously Extra	<u> </u>						
After Amend. Paid For							
Total - = $x \$ 18.00 =$	1			0.00			
Indep = $x \$ 86.00 =$				0.00			
First Presentation of Multiple Dep. + \$290.00 =			SUBTOTAL (3) 18	0.00			
Claim							
TOTAL: (\$)							
SMALL ENTITY DISCOUNT: (\$)							
SUBTOTAL (2) (\$)0.00	TOTAL (\$) 180.00						
CORRESPONDENCE ADDRESS	SIGNATURE BLOCK						
Direct all correspondence to:			Respectfully submitted,				
Patent Administrator				1			
Testa, Hurwitz & Thibeault, LLP	Date: March		Charle V. Motos				
High Street Tower-125 High Street	Reg. No.: 51,752 Jenysifer G Maitoso						
Boston, MA 02110	Tel. No.: (617) 310-8423 Attorney for the Applicants						
Tel. No.: (617) 248-7000	Fax No.: (6	17) 248-710					
Fax No.: (617) 248-7100	High Street Tower-125 High Street						
1211.511 (617) 216 7166			Boston, MA 02110				

Express Mail mailing label No. EL653442806US

PATENT Attorney Docket No. MIT-103

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Kawasaki, et al.

SERIAL NO.:

09/422,999

GROUP NO.:

1646

FILING DATE:

October 22, 1999

EXAMINER:

Murphy, J.

TITLE:

GENES INTEGRATING SIGNAL TRANSDUCTION PATHWAYS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the patents and publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.F.	2. 1.97, this statement i	s being fi	iled (CHEC	CK ONE):

within three (3) months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. 1.114; or
 after the period defined in (1) but before the mailing date of a final action or a notice of allowance under 37 C.F.R. 1.311, and
 the requisite Statement is below, OR

the requisite fee under 37 C.F.R. 1.17(p), namely \$180.00, is included herein, or

03/12/2004 SSESHE1 00000110 09422999

 \boxtimes

91 FC:1806

180.00 OP

Supplemental Information Disclosure Statement Serial No.: 09/422,999 Page 2 of 2

		fter the mailing date of a final action or notice of allowance but before the payment of the issue fee, AND
	□ t	he requisite Statement is below, AND
	☐ t	he requisite petition fee under 37 C.F.R. 1.17(p), namely \$180.00 is included herein.
PTC		ly requested that each of the patents and publications listed on the attached Former information contained herein, be made of record in this application.
		STATEMENT
	As required un	nder 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that:
	<u> </u>	Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
	<u> </u>	No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.
Reg	te: March 10, 20 g. No.: 51,752 . No.: (617) 310	Jenifer & Moitoso Attorney for Applicants Testa, Hurwitz, & Thibeault, LLP
	No.: (617) 248	



Express Mail Mailing Label No. EL653442806US Page 1 of 1

FORM I	PTO - 1	449		·		-	ATTO	ORNE	EY DOCK	KET NO.:	MIT-103			
		TAL INFORMA	TIC	N			APPI	ICA	NT(S): K	awasaki et	t al.			
DISCLOSURE STATEMENT								SERIAL NO.: 09/422,999						
 F								1G D	ATE: 10	/22/99	GRO	UP N	O.: 1646	
				U.S.	PA	TENT	DOC	UMI	ENTS					
EXAM. DOCUMENT DATE NUMBER							NAME			CLASS	SUB CLASS	1	FILING DATE IF APPROPRIATE	
	A1	4,618,598		10-21-86	6	Conn	_					04-12-82		
	A2	5,874,464		02-23-99	9	Marqu	ez et al.					06-13-95		
FOREIGN PATENT DOCUMENTS														
EXAM. INIT.		DOCUMENT NUMBER	DA	TE	COUNTR CODE		CL	ASS	SUB CLASS	FILING DATE	ABSTRACT ONLY		ENGLISH LANG (Y/N)	
	B2	WO 91/15515	10-	10-17-91 PCT		СТ				04-05-91			Y	
			OT	HER AF	RT,	JOUR	NAL .	ART	ICLES, I	ETC.				
EXAM. INIT.	ОТН	IER DOCUMEN	TS:	(Includin	g Aı	uthor, T	itle, Da	te, Re	levant Pag	ges, Place o	of Publicat	ion)		
	C33	Bos, J., (1998) "All in the family? New insights and questions regarding interconnectivity of Ras, Rap1 and Ral" The EMBO Journal, Vol. 17; No. 23, pp. 6776-6782.												
	C34	Coller et al., (1995) "New Antiplatelet Agents: Platelet GPIIb/IIIa Antagonists" Thrombosis and Haemostasis, Vol. 74 (1), pp. 302-308.												
-	C35	Newman et al., (January 1985) "Quantitation of Membrane Glycoprotein IIIa on Intact Human Platelets Using the Monoclonal Antibody, AP-3" <u>Blood</u> , Vol. 65; No. 1, pp. 227-232.												
	C36 De Bruyn, (October, 1974) "Rap1 and Ral in signal transduction; The Ras family: molecular switches in signaling cascades," Ras-like small GTPases in platelet biology, University Medical Centre of Utrecht, The Netherlands, Chapter 1; General Introduction													
C37 Zacharaski <i>et al.</i> , (1990) "Chronic Calcium Antagonist Use in Carcinoma of the Lung and Colon: A Retrospective Cohort Observational Study" Cancer Investigation, Vol. 8 (5), pp. 451-458.										on: A				
EXAMI	NER						D/	TE (CONSIDE	RED				